Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug

Mallinckrodt plc MNK subsidiary, SpecGx LLC, reported the outcome of an FDA joint advisory committee meeting on MNK-812, an abuse-deterrent, immediate-release reformulation of Roxicodone (oxycodone hydrochloride tablets USP).